EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
Plus Therapeutics Inc (NASDAQ: PSTV) reported data from the ReSPECT-LM study evaluating the company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for leptomeningeal metastases (LM).
LM is cancer in cerebrospinal fluid and leptomeninges, the membranes surrounding your brain and spinal cord.
The data were shared at the Society for Neuro-Oncology/American Society of Clinical Oncology Central Nervous System Cancer Conference.
Ten treated patients received a single escalating dose of rhenium (186Re) obisbemeda, which circulated throughout the cerebrospinal fluid (CSF) space within minutes following administration and had durable CSF retention for at least seven days.
No dose-limiting toxicities were observed, and a maximum tolerated or feasible dose was not reached.
Most adverse events were mild (Grade 1, 58.7%) or moderate (Grade 2, 24%), with the majority not related to treatment.
Five of the ten treated patients remain alive with a median overall survival (OS) of 10 months.
CSF tumor cell counts decreased from pre-dose levels 28 days after treatment by up to 91% (mean decrease = 53%).
Increases in administered dose correlated with linear increases in absorbed dose to the target tissue were observed.
Non-CNS organ dosimetry analysis of rhenium (186Re) obisbemeda confirmed these radiation levels were low, with the spleen, liver, and bladder having the most prominent rhenium (186Re) obisbemeda clearance but still significantly below critical organ toxicity levels.
The FDA has approved continued dose escalation.
Price Action: PSTV shares are down 7.99% at $2.91 premarket on the last check Friday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
